Role of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy

[en] Most of the currently available anti-osteoporosis medications promptly and significantly influence the rate of bone turnover. Biochemical markers of bone turnover now provide a high sensitivity to change, allowing the detection of these bone turnover changes within a couple of weeks. Since the anti-fracture efficacy of inhibitors of bone resorption or stimulators of bone formation appears to be largely independent of baseline bone turnover, biochemical markers do not appear to play a significant role in the selection of one particular drug, for an individual patient. However, there are consistent data showing that short-term changes in biochemical markers of bone turnover may be significant predictors of future changes in bone mineral density or fracture reduction, hence suggesting that bone turnover markers play a significant role in the monitoring of anti-osteoporosis therapy.

Disciplines :

Rheumatology

Author, co-author :

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Collette, Julien ; Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale

NEUPREZ, Audrey ; Université de Liège - ULiège > Département des Sicences de la Santé Publique > Epidémiologie et santé publique

Zegels, Brigitte ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Deroisy, Rita ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

Role of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy

Publication date :

10 February 2008

Journal title :

BONE

ISSN :

8756-3282

eISSN :

1873-2763

Publisher :

Elsevier, Netherlands

Volume :

Pages :

832-836

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.elsevier.com/wps/find/journaldescription.cws_home/525233/description#description

Available on ORBi :

since 14 April 2009

Statistics

Number of views

204 (12 by ULiège)

Number of downloads

571 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Boonen S., Body J.J., Boutsen Y., Devogelaer J.P., Goemaere S., Kaufman J.M., et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16 (2005) 239-254
Delmas P.D., and Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34 (2004) 599-604
Chen P., Miller P.D., Delmas P.D., Misurski D.A., and Krege J.H. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21 (2006) 1785-1790
Bruyère O., Roux C., Detilleux J., Slosman D.O., Spector T.D., Fardellone P., et al. Relation between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92 (2007) 3076-3081
Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J., and Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11 (2000) S2-S17
Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., et al. Markers of one resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11 (1996) 1531-1538
Bruyère O., Collette J., Delmas P., Rouillon A., Roux C., Seidel L., et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 44 (2003) 259-265
Srivastava A.K., Vliet E.L., Lewiecki E.M., Maricic M., Abdelmalek A., Gluck O., et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 21 (2005) 1015-1026
Seibel M.J. Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 27 (2006) 123-138
Bauer D.C., Gamero P.., Hochberg M.C., Santora A., Delmas P., Ewing SK., et al., for the Fracture Intervention Research Group. Pretreatment levels of bone turnover and antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21 (2006) 292-299
Schousboe J.T., Bauer D.C., Nyman J.A., Kane R.L., Melton L.J., and Ensrud K.E. Potential for bone turnover markers to costs-effectively identify and select post-menopausal osteopenic women at high risk of facture for bisphosphonate therapy. Osteoporos Int 18 (2007) 201-210
Seibel M.J., Naganathan V., Barton I., and Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19 (2004) 323-329
Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20 (2005) 962-970
Bauer D.C., Garnero P., Bilezikjan J.P., Greenspan S.L., Ensrud K.E., Rosen C.J., et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91 (2006) 1370-1375
Delmas P.D., Licata A.A., Reginster J.Y., Crans G.G., Chen P., Misurski D.A., et al. Fracture risk reduction during treatment with teriparatide is dependent of pretreatment bone turnover. Bone 39 (2006) 237-243
Dobing H., Sipos A., Jiang Y., Fahrleitner-Pammer A., Ste-Marie L.G., Gallagher J.C., et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90 (2005) 3970-3977
Rayn P., Hosking D., Thompson D., Cizza G., Wasnich R.D., McClung M., et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84 (1999) 2363-2368
Fink E., Cormier C., Steinmetz P., kindermans C., Le Bouc Y., and Souberbielle J.C. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 11 (2000) 295-303
Kim S.W., Park D.J., Park K.S., Kim S.Y., Cho B.Y., Lee H.K., et al. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52 (2005) 667-674
Greenspan S.L., parker R.A., Ferguson L., Rosen H.N., Maitland-Ramsey L., and Karpf D.B. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13 (1998) 1431-1438
Bauer D.C., Black D.M., Garnero P., Hochberg M., Ott S., Orloff J., et al., Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19 (2004) 1250-1258
Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 1051-1056
Eastell R., Hannon R.A., Garnero P., Campbell M.J., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 22 (2007) 1656-1660
Recker R., Stakkestad J.A., Chesnut C.H., Christiansen C., Skag A., Hoiseth A., et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34 (2004) 890-899
Delmas P.D., Recker R.R., Chesnut C.H., Skag A., Stakkestad J.A., Emkey R., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15 (2004) 792-798
Reginster J.Y., and Gieschke R. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. Curr Drug Metab 7 (2006) 827-836
Reginster J.Y., Adami S., Lakatos P., Greenwald M., Stepan J.J., Silverman S.L., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65 (2006) 654-661
Reginster J.Y., Felsenberg D., Cooper C., Stakkestad J.A., Miller P.D., Kendler D.L., et al. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int 17 (2006) 159-166
Papapoulos S.E., and Schimmer R.C. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy:implications from clinical studies with ibandronate. Ann Rheum Dis 66 (2007) 853-858
Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., and Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12 (2001) 922-930
Sarkar S., Reginster J.Y., Crans G.G., Diez-Perez A., Pinette K.V., and Delmas P.D. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19 (2004) 394-401
Reginster J.Y., Sarkar S., Zegels B., Henrotin Y., Bryere O., Agnusdei D., et al. Reduction in P1NP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34 (2004) 344-351
Eastell R., Krege J.H., Chen P., Glass E.V., and Reginster J.Y. Development of an algorithm for using P1NP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22 (2006) 61-66